dc.creatorComin, Maria Julieta
dc.creatorRodriguez, Juan Bautista
dc.date.accessioned2019-10-08T19:29:40Z
dc.date.accessioned2022-10-15T15:32:50Z
dc.date.available2019-10-08T19:29:40Z
dc.date.available2022-10-15T15:32:50Z
dc.date.created2019-10-08T19:29:40Z
dc.date.issued2000-06
dc.identifierComin, Maria Julieta; Rodriguez, Juan Bautista; First synthesis of (-)-neplanocin C; Pergamon-Elsevier Science Ltd; Tetrahedron; 56; 27; 6-2000; 4639-4649
dc.identifier0040-4020
dc.identifierhttp://hdl.handle.net/11336/85365
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4403366
dc.description.abstract(-)-Neplanocin C (4), a minor component of the neplanocin family of antibiotics and a lead drug for the design of several conformationally constrained nucleosides analogues, was enantioselectively synthesized starting from D-ribono-1,4-lactone via a convergent approach in twelve steps. The proton NMR spectrum of 4 was in agreement with the corresponding natural product. Calculated coupling constants obtained from ab initio molecular modeling studies and from previously published X-ray structure of neplanocin C also corresponded to the spectroscopic data.
dc.languageeng
dc.publisherPergamon-Elsevier Science Ltd
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/S0040-4020(00)00379-3
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0040402000003793
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectCARBOHYDRATES
dc.subjectENANTIOMERIC PURITY
dc.subjectNUCLEOSIDES
dc.subjectPURINES
dc.titleFirst synthesis of (-)-neplanocin C
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución